Advisory Board

Prof Chris Frampton

Chris is a co-founder and operates as the company’s Chief Scientific Advisor. A world-renowned X-Ray Crystallographer, Chris holds both academic and commercial roles and featured in Medicine Maker’s ‘Top 100 Most Influential Medicine Maker Power List” in April 2015. Chris was also a Cofounder, Director and Chief Scientific Officer of Pharmorphix Ltd (July 2003), acquired by SAFC Pharma in August 2006. Previously, Chris was Director of Strategic Marketing at Bruker AXS where he was responsible for new technology in the bio-market. More recently, Chris has taken up a Chair in Structural Chemistry and Crystal Engineering within the Wolfson Centre for Materials Processing at Brunel University and holds the post of Research Associate of Girton College, University of Cambridge. Chris is also founder and CEO of RBar3, a crystallographic consultancy.

Dr Jeffery Lindeman

Dr Lindeman is an esteemed Intellectual Property consultant and patent attourney at J. A. Lindeman LLC. A renowned thought leader in the field, Dr Lindeman is a world-leading expert in legal issues relating to pharmaceutical solid form intellectual property.

Dr Stephen Cash

Dr Cash started his career with ICI covering sales, marketing, logistics, strategic planning, and new business development. In 1992, Dr Cash led the first ICI business unit MBO, establishing Cleveland Chemicals Ltd, later sold to the Yule Catto group. Since then he has worked in new business development and technology scouting for Thomas Swan & Co Ltd, establishing world leading technologies in areas such as carbon nanotube and carbon nanofibre manufacture in addition to a number of start-up companies (Screen Technology plc, was floated on the AIM market). Dr Cash remains a non-executive director of four start-ups created during this time and sits on the advisory board of the Materials Science Department at the University of Cambridge.

Scientific Advisory Board

Nuformix is able to draw upon a broad pool of recognised world leaders covering aspects from disease expertise and clinical strategy through to drug solid form and pharmaceutical product development. The Scientific Advisory Board is comprised of a highly complimentary individuals, active in both industry and academia and who continue to research, patent and publish. Their collective expertise has enabled Nuformix to build focused portfolios around specific indications and disease fields by providing a complete view from early cocrystal target identification to eventual clinical validation.